Spexis AG announced that it has executed term sheet and issued subordinated convertible note for gross proceeds of $500,000 on February 8, 2023. The transaction included participation from SPRIM Ventures. The company issued interest-bearing subordinated convertible note financing with a term of two years and partial warrant coverage.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0634 CHF | +0.63% | +16.97% | +54.63% |
01/05 | SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication | MT |
17/04 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+54.63% | 4.73M | |
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- POLN Stock
- News Spexis AG
- Spexis AG announced that it has received $0.5 million in funding from SPRIM Ventures